Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Ellipsoid zone

  • Home
  • Ellipsoid zone
Predicting Progression in Intermediate AMD: The Crucial Role of Ellipsoid Zone Integrity and Quantitative OCT Biomarkers
Posted innews Ophthalmology

Predicting Progression in Intermediate AMD: The Crucial Role of Ellipsoid Zone Integrity and Quantitative OCT Biomarkers

Posted by MedXY By MedXY 08/11/2026
Quantitative OCT biomarkers, especially ellipsoid zone integrity and hyperreflective foci, strongly predict 2-year progression from intermediate to advanced atrophic AMD, offering potential for early risk stratification and targeted intervention.
Read More
Avacincaptad Pegol Demonstrates Efficacy in Slowing Photoreceptor Loss in Geographic Atrophy via Ellipsoid Zone Preservation
Posted innews Ophthalmology

Avacincaptad Pegol Demonstrates Efficacy in Slowing Photoreceptor Loss in Geographic Atrophy via Ellipsoid Zone Preservation

Posted by MedXY By MedXY 07/02/2026
Avacincaptad pegol significantly reduces progression of ellipsoid zone degradation and geographic atrophy lesion growth, highlighting its potential to preserve photoreceptor integrity in AMD patients.
Read More
  • Long-Term Risk of Second Primary Malignancies in Pediatric and Young Adult Differentiated Thyroid Cancer Survivors: A Four-Decade Real-World Study
  • Preserved Copeptin Kinetics with Aging: Insights into Water Homeostasis and Hyponatremia Risk in Older Adults
  • Time-Restricted Eating in Adults With Type 1 Diabetes: Safety and Glycemic Benefits Without Significant Weight Loss
  • Evaluating PCSK9 Inhibitor Effects on Outcomes in ASCVD Patients Without Prior Ischemic Events: Real-World Insights
  • Baseline Deep Capillary Plexus Ischemia as a Superior Predictor of Early Diabetic Retinopathy Complications Relative to Foveal Avascular Zone Enlargement
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in